Summary: Nearly 77,000 new cases of melanoma are expected to be diagnosed in the U.S. in 2013. This CME expert interview explores the impact of new immunotherapies on emergent management strategies that focus on optimizing outcomes for patients with inoperable or metastatic melanoma. The interview focuses on processes of T-cell activation and checkpoint controls, as well as establishing patterns of tumor response to immunotherapy. 0.5 CME Credits
